119 related articles for article (PubMed ID: 29544567)
1. Risk factors for severe neutropenia induced by combination therapy of S-1 and cisplatin in patients with advanced/recurrent gastric cancer.
Kawachi S; Shinoda Y; Kimura M; Usami E; Yoshimura T
Pharmazie; 2018 Mar; 73(3):174-177. PubMed ID: 29544567
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical care for patients undergoing s-1 plus Cisplatin therapy for unresectable recurrent gastric cancer.
Kimura M; Usami E; Yoshimura T; Yasuda T; Kaneoka Y; Teramachi H; Sugiyama T; Tsuchiya T
J Pharm Pract; 2013 Aug; 26(4):409-14. PubMed ID: 23353075
[TBL] [Abstract][Full Text] [Related]
3. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
Hironaka S; Sugimoto N; Yamaguchi K; Moriwaki T; Komatsu Y; Nishina T; Tsuji A; Nakajima TE; Gotoh M; Machida N; Bando H; Esaki T; Emi Y; Sekikawa T; Matsumoto S; Takeuchi M; Boku N; Baba H; Hyodo I
Lancet Oncol; 2016 Jan; 17(1):99-108. PubMed ID: 26640036
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer.
Uemura N; Kikuchi S; Sato Y; Ohnuma H; Okamoto K; Miyamoto H; Hirakawa M; Sagawa T; Fujikawa K; Takahashi Y; Okuda T; Minami S; Takahashi M; Okamoto T; Takada K; Miyanisi K; Takayama T; Kato J
Cancer Chemother Pharmacol; 2017 Oct; 80(4):707-713. PubMed ID: 28849257
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer.
Lee JL; Kang HJ; Kang YK; Ryu MH; Chang HM; Kim TW; Sohn HJ; Kim H; Lee JS
Cancer Chemother Pharmacol; 2008 Apr; 61(5):837-45. PubMed ID: 17579864
[TBL] [Abstract][Full Text] [Related]
6. Moderate neutropenia with S-1 plus low-dose cisplatin may predict a more favourable prognosis in advanced gastric cancer.
Nakata B; Tsuji A; Mitachi Y; Yamamitsu S; Hirata K; Takeuchi T; Shirasaka T; Hirakawa K
Clin Oncol (R Coll Radiol); 2006 Nov; 18(9):678-83. PubMed ID: 17100153
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer.
Kimura Y; Yano H; Imamura H; Fujitani K; Imano M; Tokunaga Y; Matsuoka M; Kurokawa Y; Shimokawa T; Takiuchi H; Tsujinaka T; Furukawa H
Jpn J Clin Oncol; 2013 Feb; 43(2):125-31. PubMed ID: 23225911
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
[TBL] [Abstract][Full Text] [Related]
9. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601).
Koizumi W; Nakayama N; Tanabe S; Sasaki T; Higuchi K; Nishimura K; Takagi S; Azuma M; Ae T; Ishido K; Nakatani K; Naruke A; Katada C
Cancer Chemother Pharmacol; 2012 Feb; 69(2):407-13. PubMed ID: 21796483
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of four patients with advanced gastric cancer undergoing gastrectomy after pre-operative combination chemotherapy using docetaxel, cisplatin and S-1].
Nagase T; Kanai T; Nakagawa M; Kumamoto Y; Imai S; Wada O; Honda T; Hoshino G; Atsukawa K; Sakaguchi T; Shiba T; Nonaka T; Imajyo K; Ogawa Y
Gan To Kagaku Ryoho; 2010 Nov; 37(11):2177-9. PubMed ID: 21084822
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer.
Yoshida K; Hirabayashi N; Takiyama W; Ninomiya M; Takakura N; Sakamoto J; Nishiyama M; Toge T
Anticancer Res; 2004; 24(3b):1843-51. PubMed ID: 15274365
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
Sato Y; Takayama T; Sagawa T; Takahashi Y; Ohnuma H; Okubo S; Shintani N; Tanaka S; Kida M; Sato Y; Ohta H; Miyanishi K; Sato T; Takimoto R; Kobune M; Yamaguchi K; Hirata K; Niitsu Y; Kato J
Cancer Chemother Pharmacol; 2010 Sep; 66(4):721-8. PubMed ID: 20041328
[TBL] [Abstract][Full Text] [Related]
14. [Combination chemotherapy using docetaxel, cisplatin, and S-1 for far advanced gastric cancer].
Hamakawa T; Kurokawa Y; Takiguchi S; Takahashi T; Yamasaki M; Miyata H; Nakajima K; Mori M; Dok Y
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2342-4. PubMed ID: 22202376
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution.
Nakashima K; Hironaka S; Boku N; Onozawa Y; Fukutomi A; Yamazaki K; Yasui H; Taku K; Kojima T; Machida N
Jpn J Clin Oncol; 2008 Dec; 38(12):810-5. PubMed ID: 18988666
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy of S-1 and low-dose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: a retrospective study.
Tsuji A; Shima Y; Morita S; Uchida M; Okamoto K; Morita M; Horimi T; Shirasaka T
Anticancer Res; 2008; 28(2B):1433-8. PubMed ID: 18505092
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Yoshida K; Ninomiya M; Takakura N; Hirabayashi N; Takiyama W; Sato Y; Todo S; Terashima M; Gotoh M; Sakamoto J; Nishiyama M
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3402-7. PubMed ID: 16740764
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer.
Migita K; Nashimoto A; Yabusaki H; Matsuki A; Aizawa M
Int J Clin Oncol; 2016 Feb; 21(1):102-9. PubMed ID: 26017926
[TBL] [Abstract][Full Text] [Related]
19. Risk factors contributing to the development of neutropenia in patients receiving oral trifluridine-tipiracil (TAS-102) chemotherapy for advanced/recurrent colorectal cancer.
Yasue F; Kimura M; Usami E; Iwai M; Kawachi S; Mitsuoka M; Ikeda Y; Yoshimura T
Pharmazie; 2018 Mar; 73(3):178-181. PubMed ID: 29544568
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J
Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]